Eisai's Rufinamide Estimated User Fee Deadline Is July 2006

This article was originally published in The Pink Sheet Daily

13 Sep 2005
News

John Rancourt j.rancourt@elsevier.com

Executive Summary

The company submitted its NDA for the anti-epileptic on Sept. 9 for the orphan indication of adjunctive therapy for Lennox-Gastaut syndrome and for adjunctive therapy for partial-onset seizures.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS062872

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS062872

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Eisai's Rufinamide Estimated User Fee Deadline Is July 2006

News

Executive Summary

Related Content

Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible

Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible

Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says

Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert